Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2019

View Archived Issues

FDA clears Wellspring's IND for KRAS G12C inhibitor ARS-3248

FOX-115 improves endurance of motor performances in aged mice

Phase I trial explores use of CAR T-cell therapy targeting claudin18.2 in advanced solid tumors

Shanghai Fosun Pharmaceutical studies MEK inhibitor FCN-159 in advanced melanoma

Design of an ATP-competitive chemical inhibitor of spastin

BNTA promotes generation of extracellular matrix components and delays osteoarthritis progression

Engineering B cells may enable skipping the vaccine

Forcing a multitasker to focus

Boosting PTEN foils Myc

Takeda presents new data for TAK-831

Preliminary phase II results show improved function with apraglutide in short bowel syndrome

Mutations in a subunit of DNA polymerase alpha-primase underlie an X-linked intellectual disability

Somatic variants in PDGFRB gene are involved in the physiopathology of fusiform cerebral aneurysm

Japanese researchers patent RyR1 channel blockers

Phase II results of ExPEC4V vaccine against extraintestinal pathogenic E. coli in healthy adults

Phase I trials of mRNA vaccines against H10N8 and H7N9 influenza viruses confirm immunogenicity

U.S. researchers present TGFR inhibitors

Yumanity Therapeutics synthesizes new SCD1 and SCD5 inhibitors

Interim analysis of INTELLANCE-1 study of Depatux-M in GBM shows no survival benefit

Merck & Co. divulges new HCV inhibitors

Genentech describes RIPK1 inhibitors

FDA approves Gattex for pediatric patients with short bowel syndrome

Travoprost implant OTX-TIC safe, improves intraocular pressure in phase I trial

New phase II trial studies TQB-2450 in relapsed or refractory classical Hodgkin's lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...